Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Cao, Hua ^a   Chen, Zhi Xiang ^a,b   Wang, Kai ^a   Ning, Meng Meng ^a   Zou, Qing An ^a   Feng, Ying ^a   Ye, Yang Liang ^a   Leng, Ying ^a   Shen, Jian Hua ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM DERIVATIVE; ANTIDIABETIC AGENT; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GPBAR1 PROTEIN, HUMAN; GPBAR1 PROTEIN, MOUSE; QUATERNARY AMMONIUM DERIVATIVE;

AGONISTS; ANIMAL; DISEASE MODEL; DRUG EFFECT; ENTEROENDOCRINE CELL; FEMALE; GALLBLADDER; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEK293 CELL LINE; HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INSTITUTE FOR CANCER RESEARCH MOUSE; INTESTINE; MALE; METABOLISM; MOUSE; MOUSE MUTANT; PERMEABILITY;

AMMONIUM COMPOUNDS; ANIMALS; BLOOD GLUCOSE; DISEASE MODELS, ANIMAL; ENTEROENDOCRINE CELLS; FEMALE; GALLBLADDER; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HEK293 CELLS; HOMEOSTASIS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INTESTINES; MALE; MICE; MICE, INBRED ICR; MICE, OBESE; PERMEABILITY; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84975760202     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28676     Document Type: Article

References (33)

1. Maruyama, T. et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714-719 (2002).
2. Kawamata, Y. et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435-9440 (2003).
3. Pols, T. W., Noriega, L. G., Nomura, M., Auwerx, J. & Schoonjans, K. The bile acid membrane receptor TGR5: a valuable metabolic target. Dig. Dis. 29, 37-44 (2011).
4. Keitel, V. et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia 58, 1794-1805 (2010).
5. Vassileva, G. et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem. J. 398, 423-430 (2006).
6. Katsuma, S., Hirasawa, A. & Tsujimoto, G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 329, 386-390 (2005).
7. Donnelly, D. The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br. J. Pharmacol. 166, 27-41 (2012).
8. Thomas, C. et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10, 167-177 (2009).
9. Watanabe, M. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484-489 (2006).
10. Chen, X., Lou, G., Meng, Z. & Huang, W. TGR5: a novel target for weight maintenance and glucose metabolism. Exp. Diabetes Res. 2011, 853501 (2011).
11. Pols, T. W., Noriega, L. G., Nomura, M., Auwerx, J. & Schoonjans, K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J. Hepatol. 54, 1263-1272 (2011).
12. Zhong, M. TGR5 as a therapeutic target for treating obesity. Curr. Top. Med. Chem. 10, 386-396 (2010).
13. Evans, K. A. et al. Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. J. Med. Chem. 52, 7962-7965 (2009).
14. Briere, D. A. et al. Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice. PloS One 10, e0136873 (2015).
15. Phillips, D. P. et al. Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization and chronic in vivo efficacy. J. Med. Chem. 57, 3263-3282 (2014).
16. Martin, R. E. et al. 2-Phenoxy-nicotinamides are potent agonists at the bile acid receptor GPBAR1 (TGR5). Chem Med Chem 8, 569-576 (2013).
17. Agarwal, S. et al. Discovery of a potent and orally efficacious TGR5 receptor agonist. ACS Med. Chem. Lett. 7, 51-55 (2016).
18. Fryer, R. M. et al. G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))- dependent mechanism. J. Pharmacol. Exp. Ther. 348, 421-431 (2014).
19. Li, T. et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol. Endocrinol. 25, 1066-1071 (2011).
20. Duan, H. et al. Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists. J. Med. Chem. 55, 10475-10489 (2012).
21. Piotrowski, D. W. et al. Identification of tetrahydropyrido[4,3-d]pyrimidine Amides as a new class of orally bioavailable TGR5 agonists. ACS Med. Chem. Lett. 4, 63-68 (2013).
22. Futatsugi, K. et al. Optimization of triazole-based TGR5 agonists towards orally available agents. Med Chem Comm 4, 205-210 (2013).
23. Xu, Y. Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases. J. Med. Chem. doi: 10.1021/acs. jmedchem.5b00342 (2016).
24. Hodge, R. J. & Nunez, D. J. The Therapeutic Potential of TGR5 Agonists. Hope or Hype? Diabetes Obes. Metab. doi: 10.1111/dom.12636 (2016).
25. Duan, H. et al. Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes. J. Med. Chem. 58, 3315-3328 (2015).
26. Handelsman, Y. Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care 34 Suppl 2, S244-250 (2011).
27. Tziomalos, K. Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World J. Hepatol. 6, 738-744 (2014).
28. Hansen, M., Sonne, D. P. & Knop, F. K. Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes. Curr. Diab. Rep. 14, 482-490 (2014).
29. Harach, T. et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci. Rep. 2, 430-436 (2012).
30. Prawitt, J., Caron, S. & Staels, B. Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization. Trends Endocrinol. Metab. 25, 235-244 (2014).
31. Boliu, V. et al. Inventors; Exelixis, Inc., assignee. TGR5 agonists. Patent Cooperation Treaty (PCT) WO2011071565A1. 2011 Jun 16.
32. Flatt, B. T. & Mohan, R. Inventors; Exelixis, Inc., assignee. TGR5 agonists: imidazole and triazole compounds containing a quaternary nitrogen. Patent Cooperation Treaty (PCT) WO2014100021A1. 2014 Jun 26.
33. Flatt, B. T. & Mohan, R. Inventors; Exelixis, Inc., assignee. TGR5 agonists having an imidazole or triazole core with subtituent having a quaternary nitrogen. Patent Cooperation Treaty (PCT) WO2014100025A1. 2014 Jun 26.